文献速递胸部肿瘤

III期NSCLC放化疗后度伐利尤单抗治疗中ctDNA-MRD检测研究

ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab.
PubMed 文献 · J Thorac Oncol · 2026-06-23

这项前瞻性多中心研究纳入84例不可切除III期NSCLC患者,放化疗后接受度伐利尤单抗治疗,连续采集659份血浆样本行ctDNA-MRD检测。结果显示,度伐利尤单抗第7周期前及治疗结束后3个月可检出ctDNA与更差PFS显著相关,而放化疗后至度伐利尤单抗开始前检出ctDNA无预后价值。

要点

  • 度伐利尤单抗治疗6个月时ctDNA阳性与PFS显著更差相关(HR 2.45)。
  • 治疗结束后3个月ctDNA阳性与PFS显著更差强相关(HR 5.37)。
  • 放化疗后、度伐利尤单抗前ctDNA检测无预后意义。

核心结论

  • 度伐利尤单抗治疗期间及治疗后检出ctDNA与不可切除III期NSCLC患者PFS显著缩短相关。
  • 连续ctDNA-MRD评估可能有助于识别高复发风险、或可从替代或强化治疗中获益的患者。

研究设计与样本

  • 前瞻性多中心研究,纳入84例不可切除III期NSCLC患者,放化疗后接受度伐利尤单抗治疗。
  • 共分析659份血浆样本,采集时间包括筛查时、放化疗后、度伐利尤单抗治疗期间预设时间点及治疗后随访。
  • 采用肿瘤不可知、杂交捕获、个体化ctDNA-MRD检测,将样本分类为ctDNA检出(MRD阳性)或未检出(MRD阴性)。

主要发现

  • 度伐利尤单抗第7周期前(治疗6个月后)可检出ctDNA与PFS更差显著相关(HR 2.45,95%CI 1.18-5.11,p=0.013)。
  • 治疗完成后3个月可检出ctDNA与PFS更差显著相关(HR 5.37,95%CI 1.93-14.93,p<0.001)。
  • 放化疗后至度伐利尤单抗开始前检出ctDNA无预后意义(HR 1.38,95%CI 0.78-2.41,p=0.269)。
  • 纳入所有放化疗后样本的多变量时间依赖Cox模型显示,可检出ctDNA与进展风险近三倍升高相关(HR 2.95,95%CI 1.69-5.15,p<0.001)。

临床怎么用

  • 可在度伐利尤单抗治疗期间及治疗结束后采用连续ctDNA-MRD检测识别高复发风险患者。
  • 对ctDNA-MRD阳性患者,可考虑在前瞻性临床试验中探索替代或强化治疗策略。
  • 放化疗后至度伐利尤单抗前单次ctDNA检测不宜用于预后分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The benefit of durvalumab after chemoradiotherapy (CRT) varies widely in unresectable stage III NSCLC. Circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) detection may help identify patients at high risk of early treatment failure during and after durvalumab. METHODS: In this prospective multicenter study, patients with unresectable stage III NSCLC received CRT followed by durvalumab. Plasma samples were collected at screening, after CRT, at predefined time points during durvalumab, and during post-treatment follow-up. A tumor-agnostic, hybrid-capture ctDNA MRD assay personalized to each patient classified samples as ctDNA detected (MRD positive) or not detected (MRD negative). RESULTS: A total of 659 plasma samples from 84 patients were analyzed. Detectable ctDNA before the seventh cycle of durvalumab (after 6 mo of treatment) and 3 months after treatment completion was strongly associated with inferior progression-free survival (PFS) (hazard ratio [HR]: 2.45, 95% confidence interval [CI]: 1.18-5.11, p = 0.013 and HR: 5.37, 95% CI: 1.93-14.93, p < 0.001, respectively). Detection of ctDNA after CRT but before durvalumab initiation was not prognostic (HR: 1.38, 95% CI: 0.78-2.41, p = 0.269). In a multivariable time-dependent Cox model incorporating all post-CRT samples, detectable ctDNA was associated with a nearly threefold higher risk of progression (HR: 2.95, 95% CI: 1.69-5.15, p < 0.001). CONCLUSIONS: Detectable ctDNA during and after durvalumab was associated with markedly shorter PFS in unresectable stage III NSCLC. Serial ctDNA-based MRD assessment may help identify patients at high risk of relapse who could benefit from alternative or intensified treatment strategies, ideally within prospective clinical trials. GOV IDENTIFIER: NCT04392505.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Horndalsveen H, Haakensen VD, Madebo T, et al. ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab. J Thorac Oncol. 2026. PMID: 42336205. doi:10.1016/j.jtho.2026.103992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。